Allan Bradley, T-Therapeutics CEO
November 15, 2023 05:46 AM ESTUpdated 07:08 AM
Financing
Startups

Sanofi-backed T-Ther­a­peu­tics bags $59M in Se­ries A to un­lock po­ten­tial of TCR ther­a­peu­tics: #Jef­feries23

Ayisha Sharma

News Reporter

LON­DON — T-Ther­a­peu­tics has raised £48 mil­lion ($59 mil­lion) in a Se­ries A round sup­port­ed by a Big Phar­ma in­vestor to dis­cov­er and de­vel­op new …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times